Europace 2023 25 291299 httpsdoiorg101093europaceeuac217 CLINICAL RESEARCH Incidence thyroid dysfunction following initiation amiodarone treatment patients heart failure nationwide cohort study Sam Aiyad Ali Rasmus Rørth Ulrik Madvig Mogensen Finn Gustafsson 1 Mads Ersbøll1 Naja Emborg Vinding 1 Christian Selmer 2 Lucas Malta Westergaard 1 1 Jawad Haider Butt 1 3 Peter E Weeke 1 Christian Jøns 1 1 Emil Fosbøl 1 Lars Køber 1 Søren Lund Kristensen 1 1Department Cardiology Rigshospitalet University Copenhagen Blegdamsvej 9 Copenhagen 2100 Denmark 2Department Endocrinology Bispebjerg Frederiksberg Hospital Copenhagen Denmark 3Department Cardiology Zealand University Hospital Roskilde Denmark Received 25 August 2022 accepted revision 4 November 2022 online publishaheadofprint 12 December 2022 Aims Thyroid dysfunction considered frequent complication amiodarone treatment data occurrence outside clinical trials sparse The present study aimed examine incidence thyroid dysfunction following initiation amiodarone treatment nationwide cohort patients heart failure HF Methods In Danish registries identified patients firsttime amiodarone treatment period 200018 results prior thyroid disease medication The primary outcome composite thyroid diagnoses initiation thyroid drugs Outcomes assessed 1year followup patients free events year landmark analysis subsequent 5 years We included 43 724 patients firsttime amiodarone treatment 16 939 38 HF At 1year followup cumulative incidence adjusted hazard ratio HR primary outcome 53 137 95 confidence interval 125150 patients history HF 42 HF reference In 1year landmark analysis subsequent 5year cumulative incidences adjusted HRs primary outcome 53 ref erence patients 1year accumulated dose 2738 g corresponding average daily dose ADD 75 mg 140 HR 274 246305 27384563 g ADD 75125 mg 200 HR 416 377459 45646388 g ADD 126175 mg 245 HR 530 482590 6388 g ADD 175 mg Conclusion Among patients initiated amiodarone treatment 5 thyroid dysfunction 1year followup slightly higher incidence HF A doseresponse relationship observed 1year accumulated amiodar dose subsequent 5year cumulative incidence thyroid dysfunction Keywords Amiodarone Hyperthyroidism Hypothyroidism Heart failure Corresponding author Tel 45 93603832 Email address samaiyadaliicloudcom The Authors 2022 Published Oxford University Press behalf European Society Cardiology This Open Access article distributed terms Creative Commons AttributionNonCommercial License httpscreativecommonsorglicensesbync40 permits noncommercial reuse distribution reproduction medium provided original work properly cited For commercial reuse contact journalspermissionsoupcom 292 SA Ali et al Whats new Around 5 patients prior history thyroid disease initiated amiodarone treatment diagnosed andor treated thyroid drugs 1 year The presence heart failure HF associated slightly high er risk thyroid dysfunction patients HF sick likely receiver higher accumulated doses amiodarone Longterm risk thyroid dysfunction doseresponse relation ship accumulated amiodarone dose year treatment Shortterm amiodarone treatment reflected low accumu lated dose associated modest risk thyroid dysfunction Introduction Cardiac arrhythmias major cause morbidity mortality par ticularly patients heart failure HF Amiodarone effective short longterm rhythm control supraventricular tachyarrhyth mias following event ventricular tachycardia event worsening HF tachycardiainduced cardiomy opathy suspected13 Amiodarone benzofuran iodinerich drug aside beneficial effects cardiac arrhythmias known ad verse effects145 Hyperthyroidism hypothyroidism recognized complications amiodarone treatment reported overall risk ranging 2 24268 Other complications include photosensitivity frequently pulmonary fibrosis liver affec tion elevated transaminase levels Due adverse effects amiodarone treatment requires close monitoring longterm treat ment avoided younger patients126910 While relation amiodarone risk thyroid dysfunc tion described clinical trials populationbased data short longterm adverse effects comers initiating oral amiodarone treatment lacking81114 In addition little known risk thyroid dysfunction correlates dose amiodarone accumulate time Therefore set utilize Danish nationwide registries investigate magnitude thyroid dysfunction risk associated amiodarone treatment patients HF order guide clinicians improve patient information Methods Data sources The Danish national administrative registries contain data Danish sidents accurate linkage multiple nationwide registries pos sible unique personal identification number Danish residents given date birth immigration In present study obtained data linkage following registries Danish Civil Registration System contains data birth date sex vi tal status date death15 ii Danish National Patient Registry holds information hospital admissions 1977 patient contacts 1995 diagnosis codes based International Classification Diseases ICD8 ICD10 codes sur gical procedures classified according Nordic MedicoStatistical Committee 199616 iii Danish National Prescription Registry contains detailed information dispensing date strength quantity claimed drug prescriptions Denmark17 Study population exposure The study population comprised Danish residents aged 1890 years firsttime treatment amiodarone 2000 2018 prior history thyroid dysfunction thyroid drug usage The study popu lation categorized according presence HF time prior index date Figure 1 In patients alive thyroid dysfunction 1year followup performed landmark analysis examining subse quent 5year outcomes Eligible patients grouped according accumulated amiodarone dose year follows 2738 g corresponding average daily dose ADD 75 mg ii 27384563 g ADD 75125 mg 45646388 g ADD 126175 mg 6388 g ADD 175 mg To groups perspective reflect standard daily dose 200 mg 45 4575 76105 105 months year treatment respectively reflect lower doses longer duration conversely shorter duration higher dose treatment Figure 1 Flow chart study population HF heart failure All Danish residents firsttime treatment amiodaronebetween 1 January 2000 31 December 2018N 47 2733549 patients excluded2570 prior thyroid diagnosis ormedication979 age 18 90 yearsAll Danish residents firsttime treatment amiodaronebetween 1 January 2000 31 December 2018without prior thyroid diagnosis mediciationN 43 724With HFN 16 939Without HFN 26 785 Amiodarone thyroid dysfunction 293 Concomitant pharmacotherapy comorbidity Patient medical history obtained Danish National Patient Registry based inhospital outpatient diagnosis codes time prior index date Supplementary material online Tables S1 S2 Concomitant pharmacotherapy defined Danish National Prescription Registry claimed prescriptions 180 days prior index date Supplementary material online Table S3 Heart failure defined inhospital outpatient diagnosis codes time prior index date Aborted cardiac arrest defined diagnosis cardiac arrest ventricular fibrillation Hypothyroidism defined redeemed prescription levothyroxine hypothyroidism diagnosis hyperthyroidism defined deemed prescription antithyroid medication diagnosis hyperthyroidism thyroiditis previously18 Diabetes defined redeemed prescription antidiabetic medication diabetes diagnosis Sensitivity analyses Four supplementary analyses conducted First consecutive matches sex age HF conducted 11 ratio patients firsttime treatment amiodarone primary cohort matched controls prior thyroid diagnosis medication ii primary cohort matched controls history cardiac arrhythmias prior thyroid diagnosis medication Second repeated 1year outcome analyses restricting patients HF strati fied HF severity defined daily dose furosemide furosemide daily dose 40 mg ii furosemide daily dose 4080 mg iii furosemide daily dose 81160 mg iv furosemide daily dose 160 mg Third repeated landmark analysis cohort restricted patients receive amiodarone treatment year follow Fourth order test shortterm highdose amiodarone associated higher risk thyroid disorders repeated landmark analysis start 3 6 9 months respectively 1 year start amiodarone treatment Outcomes The primary outcome composite redeemed prescription ei ther levothyroxine antithyroid medication inhospital outpatient contact following diagnoses hypothyroidism hyperthy roidism thyroiditis The secondary outcomes hypothyroidism ii hyperthyroidism iii allcause death Finally exploratory comes observed inhospital outpatient contact diag nosis pulmonary fibrosis ii inhospital outpatient contact diagnosis liver disease For analyses excluded patients history outcomes prior study start In Denmark ini tiation monitoring amiodarone treatment restricted outpatient cardiology departments measurement thyroidstimulating hormone TSH liver parameters recommended prior initiation amiodarone treatment 6 months ongoing treatment The primary cohort followed date treatment initiation amiodarone index date maximum 1 year oc currence primary outcome death end study period 31 December 2018 Those events year eligible landmark analysis started 1 year index date fol lowed patients 5 years occurrence primary come death end study period 31 December 2018 whichever came Statistics Baseline characteristics reported numbers percentages categorical variables medians 2575th percentiles continuous variables Differences baseline characteristics HF tested χ2 test categorical variables Mann Whitney test continuous variables Cumulative incidence curves drawn composite primary secondary outcomes AalenJohansen estimator assessing death competing risk Differences groups assessed Grays test The cumula tive incidence allcause death examined KaplanMeier esti mates differences groups assessed logrank test19 A multivariableadjusted Cox proportional hazard analysis ap plied compare risk groups Analysis adjusted following covariates sex age calendar period prior hospital admission reason 2 weeks treatment statins known comorbidities prior dex date including ischaemic heart disease peripheral artery disease dia betes malignancy chronic renal disease chronic obstructive pulmonary disease stroke In primary analysis patients HF reference group landmark analysis group patients accumulated 1year dose 2738 g ADD 75 mg served reference group The proportional hazards assumption exam ined graphically log log g survival function vs time plots exposure variable valid adjusted Cox analysis Relevant teractions including sex calendar period tested insignifi All statistical analyses performed SAS statistical software version 94 Cary NC USA R version 361 The R Foundation Vienna Austria For analysis twotailed Pvalue 005 sidered statistically significant Ethics In Denmark registerbased studies conducted sole purpose scientific research require ethical approval informed consent law However study approved data responsible institute Capital Region Denmarkapproval number P2019191 accord ance General Data Protection Regulation Results Baseline characteristics From 1 January 2000 31 December 2018 43 724 patients time treatment amiodarone identified median age 71 years 2575th percentile 6377 69 men 16 939 38 history HF Compared patients HF patients history HF similar age 71 vs 70 years men 74 vs 65 likely history ventricular tachycardia 19 vs 60 ischaemic heart disease 60 vs 43 aborted cardiac ar rest 80 vs 30 Pvalues 0001 There little difference history atrial fibrillation common groups 72 vs 73 Cardiovascular pharmacotherapy noncardiac morbidities frequent patients HF HF Table 1 In landmark analysis 36 697 patients cluded median age 70 years 2575th percentile 62 76 69 men 15 282 42 HF The baseline characteristics patients included landmark analysis listed Supplementary material online Table S4 Primary outcome The crude cumulative 1year incidence primary composite thy roid outcome 53 patients history HF 42 HF Figure 2 Compared patients HF ad justed analysis yielded increased associated rate primary com posite thyroid outcome patients history HF hazard ratio HR 137 95 confidence interval CI 125150 Details occur rence hypo hyperthyroidism listed Table 2 The corre sponding 1year incidence primary composite thyroid outcome 05 controls general population matched age sex history HF Supplementary material online Tables S5 S6 In landmark analysis crude cumulative 5year incidence primary composite thyroid outcome 53 140 200 245 patients 1year accumulated dose 2738 g ADD 75 mg 27384563 g ADD 75125 mg 45646388 g ADD 126175 mg 6388 g ADD 175 mg respectively Figure 3 Compared 1year accumulated dose 2738 g ADD 75 mg corresponding associated rates primary composite thyroid outcome HR 294 SA Ali et al Table 1 Baseline characteristics study population Total n 43 724 With HF n 16 939 38 Without HF n 26 785 62 Pvalue Sex men Age median 2575th percentile years Hospital admission reason 2 weeks Calendar period 200005 200611 201218 Prior cardiac procedures Coronary angiography PCI CABG Heart valve surgery Radiofrequency ablation ICD CRTP CRTD ICD CRTPD Brady pacemaker Medical history Atrial fibrillation Unspecified supraventricular tachycardia Ventricular tachycardia Aborted cardiac arrest Unspecified arrhythmias Ischaemic heart disease Hypertension Stroke Diabetes Peripheral artery disease Bleeding COPD Malignancy Chronic renal disease Liver disease Pulmonary fibrosis Concomitant pharmacotherapy Betablockers RAS inhibitors Mineralocorticoid receptor antagonists Digoxin Loop diuretics Statins Thiazides Calcium channel blockers Oral anticoagulant therapy Aspirin 29 946 690 71 6377 29 627 678 11 616 266 14 000 320 18 108 414 20 935 479 5976 137 7497 171 4185 96 3026 69 3422 78 305 07 1664 38 5292 121 2648 61 12 443 740 71 6378 11 932 704 4575 270 5141 3035 7223 4264 9694 572 3201 189 2692 159 1405 83 825 49 2702 160 288 17 687 41 1326 78 3587 212 31 952 731 12 273 725 5458 125 4806 110 2080 45 6518 149 21 653 495 19 496 421 5963 136 7058 161 3032 69 7317 167 6527 149 6670 153 3496 80 954 22 154 04 26 859 614 20 949 479 4805 110 8987 206 14 804 339 17 468 400 7191 164 11 174 256 19 298 441 17 774 407 1741 103 3198 190 1359 80 2965 175 10 102 600 7514 420 2644 160 3585 220 1603 95 3186 188 3330 197 2299 136 2026 120 449 27 81 05 10 796 637 10 572 624 3925 232 4549 269 9353 552 7128 421 2358 139 3551 210 7493 442 7468 441 17 503 650 70 6277 17 695 661 7041 263 8859 331 10 885 406 11 241 420 2775 104 4805 179 2780 104 2201 82 720 27 17 01 977 36 1322 49 1705 64 19 679 735 3717 139 1608 60 721 30 3553 133 11 551 430 11 982 423 3319 124 3472 130 1429 53 4131 154 3197 119 4371 163 1470 55 505 19 73 03 16 063 600 10 377 387 880 33 4438 166 5451 204 10 340 386 4833 180 7623 285 11 805 441 10 306 385 00001 NA 00001 NA NA NA 00001 00001 00001 00001 00001 00001 00001 0032 00001 00001 0024 00001 00001 00001 00001 00001 0440 00001 00001 00001 00001 00001 00001 00001 00001 00005 00001 00001 00001 00001 00001 00001 00001 00001 0754 00001 CABG coronary artery bypass graft surgery COPD chronic obstructive pulmonary disease CRT cardiac resynchronization therapy HF heart failure ICD implantable cardioverter defibrillator PCI percutaneous coronary intervention RAS reninangiotensin Amiodarone thyroid dysfunction 295 Figure 2 Cumulative 1year incidence composite primary thyroid outcome according presence heart failure HF heart failure 274 95 CI 246305 HR 416 95 CI 377459 HR 528 95 CI 482590 respectively Table 3 The median accumulated dose amiodarone 7367 patients primary composite thyroid outcome time event 382 g 2575th percentile 581236 g Secondary outcomes The crude cumulative 1year incidence allcause death 180 patients history HF 100 patients HF reference adjusted HR 166 95 CI 157 176 Supplementary material online Figure S1 The crude cumula tive 1year incidence hypothyroidism 30 patients tory HF 20 HF corresponding numbers hyperthyroidism 23 23 respectively Table 2 In landmark analysis crude cumulative 5year incidence allcause death 214 272 340 331 patients 1year accumulated dose 2738 g ADD 75 mg 27384563 g ADD 75125 mg 45646388 g ADD 126175 mg 6388 g ADD 175 mg respectively Supplementary material online Figure S2 The crude cumulative 5year incidences hypothyroidism hyperthyroidism according accumulated dose amiodarone listed Table 3 Each composite primary outcome listed Table 3 Sensitivity analyses First crude cumulative 1year incidence primary composite thyroid outcome lower age sex HFmatched sample general population 05 matched control cardiac arrhythmias treated amiodarone 06 Supplementary material online Tables S5 S6 Second restricted analysis include HF patients stratified daily dose furosemide 40 mg ii 4080 mg iii 81160 mg iv 160 mg The corresponding crude cumulative 1year inci dences composite thyroid outcome 52 51 57 55 allcause deaths 13 23 25 33 respectively Supplementary material online Figures S3 S4 Third formed modified landmark analysis patients treated amiodarone year censored crude cumulative 5year incidence primary composite thyroid outcome 46 102 134 163 Supplementary material online Figure S5 Table S7 Fourth performed landmark analyses start ing 3 6 9 months according accumulated doses patients groups highest accumulated doses ADD 175 mg 5year incidence thyroid dysfunction 18 21 23 compared 245 primary landmark analysis Supplementary material online Figures S6S8 Exploratory outcomes The crude cumulative 1year incidences liver disease 05 vs 03 HF pulmonary fibrosis 02 vs 01 differ substantively according HF Table 2 In landmark ana lysis relation accumulated amiodarone dose year risk liver disease pulmonary fibrosis Table 3 Discussion In nationwide study 5 patients initiated treatment amiodarone diagnosed treated thyroid dysfunction 1 year followup A history HF time amio darone treatment associated higher likelihood prior ven tricular arrhythmia higher accumulated doses amiodarone Without HFWith HFWithout HF26 78524 87823 69722 63321 80016 93915 19314 08413 21012 451With HF10755Primary composite thyroid outcome 250091No risk182Days study start273365Grays test p 0001 296 SA Ali et al Adjusted modela HR 95 CI Pvalue Table 2 Oneyear clinical outcomes No crude cumulative 1year incidence Total n 43 724 With HF n 16 939 Without HF n 26 785 Primary outcome Composite thyroid outcome 1945 45 868 53 1077 42 137 125150 00001 Secondary outcomes Composite hypothyroidism Composite hyperthyroidism Any thyroid diagnosis Hypothyroidism Hyperthyroidism Thyroiditis Any thyroid treatment Levothyroxine Propylthiouracil Methimazole Allcause death Exploratory outcomes Liver disease Pulmonary fibrosis 969 22 993 23 1433 33 689 16 696 16 48 01 879 20 404 09 3b 470 11 494 30 384 23 623 38 335 20 270 16 18 01 408 25 227 13 3b 178 11 475 20 609 23 810 31 354 14 426 16 30 01 471 18 177 07 3b 292 11 5432 124 2931 180 2501 96 173 152200 00001 110 095124 021 133 120148 00001 161 138187 00001 112 095131 017 NA 142 124163 00001 203 166249 00001 NA 103 085125 074 166 157176 00001 166 04 83 02 88 05 42 02 78 03 41 01 NA NA This table shows absolute numbers No crude cumulative 1year incidence adjusted HRs primary secondary exploratory outcomes individually composite according HF CI confidence interval HF heart failure HR hazard ratio aFully adjusted sex age calendar period hospital admission reason 2 weeks ischaemic heart disease peripheral artery disease diabetes malignancy chronic obstructive pulmonary disease chronic renal disease stroke treatment statins bThe exact number patients withheld maintain confidentiality Figure 3 Cumulative 5year incidence primary composite thyroid outcome landmark analysis starting 1year followup Accumulated dose average daily dose 2738 g 75 mg27384563 g 75125 mg45646388 g 126175 mg 6388 g 175 mg15 110120 95107 33940382347175653348824080339229002447653850594092331827752314851668375449440136563110 2738 g27384563 g45646388 g 6388 g3022515Primary composite thyroid outcome 75001No risk2Years345Grays test p 0001 Amiodarone thyroid dysfunction 297 I C 5 9 R H d e t s u d j e c n e d c n r e y 5 e v t l u m u c e d u r c o N 6 1 5 8 n g m 5 7 1 D D A g 8 8 3 6 8 3 5 6 n g m 5 7 1 6 2 1 D D A g 8 8 3 6 4 6 5 4 3 3 5 6 n g m 5 2 1 5 7 D D A g 3 6 5 4 8 3 7 2 0 1 1 5 1 n g m 5 7 D D A g 8 3 7 2 e s o d r e y 1 l d e t u m u c c A 3 2 8 1 8 1 2 4 7 9 6 6 3 n e m o c t u o y r m r P 1 0 0 0 0 P 0 9 5 2 8 4 8 2 5 5 4 2 0 3 8 1 1 0 0 0 0 P 9 5 4 7 7 3 6 1 4 0 0 2 8 7 0 1 1 0 0 0 0 P 5 0 3 6 4 2 4 7 2 0 4 1 8 9 6 f e R 0 0 1 3 5 6 3 6 d o r y h t e t s o p m o C s e m o c t u o y r d n o c e S e m o c t u o 1 0 0 0 0 P 7 8 7 5 1 6 5 9 6 4 6 1 1 3 2 1 1 0 0 0 0 P 8 5 6 3 2 5 0 0 6 0 7 1 3 6 2 1 1 0 0 0 0 P 4 3 4 0 1 3 4 6 3 8 5 5 2 4 1 0 0 0 0 P 3 6 8 2 3 6 0 4 7 0 1 1 8 8 7 A N 0 5 1 0 0 0 0 P 0 0 6 4 7 4 0 3 5 1 8 1 2 3 3 1 1 0 0 0 0 P 1 0 0 0 0 P 0 8 5 4 4 4 4 0 5 0 0 4 0 1 5 3 2 1 5 7 6 0 5 4 2 3 1 1 2 7 1 0 0 0 0 P 1 0 0 0 0 P 6 7 3 7 5 2 0 1 6 1 3 4 1 1 3 0 5 5 6 2 0 1 5 5 7 3 1 4 A N 3 4 1 0 0 0 0 P 0 7 4 1 7 3 7 1 4 4 4 1 5 7 7 1 0 0 0 0 P 0 9 3 6 9 2 0 4 3 0 9 4 6 6 1 0 0 0 0 P 3 4 3 5 5 2 6 9 2 0 8 4 2 4 1 0 0 0 0 P 5 5 3 0 5 2 A N 0 2 0 0 3 1 5 4 7 3 1 0 0 0 0 P 0 4 3 1 3 2 0 8 2 9 4 8 5 2 A N 0 1 1 0 0 0 0 P 1 0 0 0 0 P 1 0 0 0 0 P 1 0 0 0 0 P 1 0 0 0 0 P 1 0 0 0 0 P 1 0 0 0 0 P 6 6 2 3 9 1 0 6 3 8 6 2 0 3 3 2 5 2 3 6 2 3 7 1 0 0 4 2 7 2 1 1 3 0 4 2 3 8 2 0 9 1 1 0 0 0 0 P 1 9 7 0 0 6 6 8 6 0 3 1 8 3 9 1 0 0 0 0 P 4 8 5 0 3 4 1 0 5 4 9 7 0 5 1 0 0 0 0 P 0 4 3 2 4 2 0 3 2 1 6 0 0 3 0 1 3 1 8 6 1 4 0 9 2 3 9 0 7 4 3 1 2 5 3 9 6 1 0 3 3 4 5 5 7 2 A N 6 2 3 7 2 9 9 6 8 4 1 3 2 0 4 3 9 1 0 0 3 6 5 4 8 2 A N 9 f e R 0 0 1 0 3 9 0 3 f e R 0 0 1 0 3 8 3 3 m s d o r y h t o p y h e t s o p m o C e t s o p m o C f e R 0 0 1 3 3 8 9 3 s s o n g d d o r y h t y n A m s d o r y h t r e p y h f e R 0 0 1 6 1 6 8 1 m s d o r y h t o p y H f e R 0 0 1 7 1 5 0 2 m s d o r y h t r e p y H A N 7 s t d o r y h T f e R 0 0 1 7 3 2 4 4 t n e m t e r t d o r y h t y n A f e R 0 0 1 6 1 9 8 1 A N b 3 f e R 0 0 1 1 2 0 5 2 e n x o r y h t o v e L l c r u o h t l y p o r P l e o z m h t e M 1 0 0 0 0 P 0 5 1 4 3 1 2 4 1 1 3 3 7 4 4 2 1 0 0 0 0 P 1 5 1 3 3 1 2 4 1 0 4 3 8 9 7 1 1 0 0 0 0 P 1 3 1 4 1 1 2 2 1 2 7 2 2 3 3 1 f e R 0 0 1 4 1 2 7 8 4 2 h t e d e s u c l l A 2 1 2 9 6 0 8 4 3 1 8 6 6 0 5 3 3 1 3 6 5 0 4 2 e c n e r e f e r f e R o t r d r z h R H l v r e t n e c n e d fi n o c I C e s o d y l d e g r e v D D A 1 1 0 3 1 3 0 5 4 s e m o c t u o y r o t r o p x E l s s o r b fi y r n o m u P l e s e s d r e v L s n t t s h t w t n e m t e r t d n e k o r t s e s e s d l n e r c n o r h c e s e s d y r n o m u p l e v t c u r t s b o c n o r h c y c n n g l m s e t e b d e s e s d y r e t r l r e h p r e p e s e s d t r e h c m e h c s e g x e s r o f d e t s u d j y t l t n e d fi n o c n t n m o t l d e h h t w s s t n e t p f o r e b m u n t c x e y l l u F e h T b p u w o l l o f r e y 1 t g n t r t s s s y n l k r m d n l e h t m o r f s e m o c t u o m r e t g n o L l 3 e b T 298 SA Ali et al year significantly higher risk thyroid dysfunction allcause death The longterm risk thyroid dysfunction dose response relationship accumulated dose amiodarone year treatment Compared matched controls general population pa tients treated amiodarone 10 higher incidence thyroid dysfunction comorbidity higher risk allcause death When stratified patients HF according daily dose furosemide study start proxy HF severity clear relation 1year risk death incidence thyroid dysfunction The relation amiodarone treatment 1year inci dence thyroid events previously evaluated Randomized DoubleBlind Trial Evaluate Efficacy Safety Dronedarone versus Amiodarone DIONYSOS 59 amiodarone group compared 08 dronedarone group veloped thyroid events7 A metaanalysis 13 randomized trials volving 6553 patients mean followup 1 year showed higher net absolute difference amiodarone group compared placebo group hypothyroidism 59 09 hyperthy roidism 11 lung infiltrates 06 liver toxicity20 In post hoc analysis Doubleblind Sotalol Amiodarone Atrial Fibrillation Efficacy Trial SAFETrial 5 amiodaronetreated patients developed hypothyroidism compared 03 controls treated sotalol placebo 53 amiodar group developed hyperthyroidism compared 24 trol group21 In line studies 22 experienced hypothyroidism 23 hyperthyroidism 02 pulmonary fibrosis 04 liver toxicity year amiodarone treatment Notably risk pulmonary fibrosis liver disease increase higher accumulated doses amiodarone albeit caveat complications rare Earlier studies report inconsistent results accumulated amiodarone dose needed cause thyroid dysfunction substantial fraction patients Notably metaanalysis randomized trials involving 1465 patients lowdose amiodarone ADD 400 mg ported thyroid dysfunction 37 amiodarone group vs 04 placebo group mean followup 1 year22 A small nested casecontrol study accumulated amiodarone dose 144 g related higher risk thyroid dysfunction particularly hyper thyroidism14 The median accumulated dose amiodarone time thyroid dysfunction study 38 g mentioned study fully consistent finding clear dosere sponse relationship accumulated dose amiodarone year subsequent risk thyroid dysfunction Further evaluated shorterduration highdose amiodarone treatment associated higher risk evident In landmark analysis censored patients treated amiodar year 5year incidence thyroid dysfunction somewhat lower For group lowest accumulated dose 2738 g ADD 75 mg 5year incidence remained unchanged 5 indicating shortterm amiodarone treatment relatively low risk In present study slightly higher 1year incidence composite primary thyroid outcome patients HF compared HF 53 vs 42 Patients severe HF defined higher doses loop diuretics higher incidence thyroid dysfunction Limitations The Danish administrative registries validated high quality high positive predictive values 80 HF cardiac arrhythmia cardiovascular diseases Supplementary material online Table S82325 The accuracy thyroid disorder diagnoses validated Danish registries Canadian study diagnosis hypothyroidism shown positive predictive value 9326 Similarly diagnoses exploratory comes liver disease pulmonary fibrosis validated We lacked information important clinical parameters HF severity ejection fraction blood pressure kidney function natriuretic peptides better characterization thyroid outcomes thyroid ultrasound scintigraph reports la boratory measurements TSH triiodothyronine T3 free T3 thyroxine T4 free T4 thyroid antibodies available Thus differentiation amiodaroneinduced hypothyroidism amiodaroneinduced thyrotoxicosis Types 1 2 possible Detection previously overlooked thyroid diseases frequent testing initiation amiodarone treatment fully ruled thyroid testing prior initiation amiodarone treatment recommended Denmark Conclusions In nationwide study 5 patients initiated treatment amiodarone thyroid dysfunction 1year follow In addition doseresponse relationship observed accumulated dose amiodarone year sub sequent 5year incidence thyroid dysfunction Patients HF initiated amiodarone received higher accumulated doses amiodarone displayed significantly higher associated rates thyroid dysfunc tion allcause death Supplementary material Supplementary material available Europace online Funding The work supported internal grant Department Cardiology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark The funding source role design conduct analysis reporting submitted work Conflict JHB received advisory board honoraria Bayer unrelated submitted work EF received independent search grant Novo Nordisk Foundation unrelated submitted work LK received speakers honoraria Novo Novartis AstraZeneca Boehringer unrelated submitted work SLK ceived speakers honoraria Astra Zeneca outside submitted work All remaining authors declared conflicts Data availability The study conducted Statistics Denmarks registers We authorized online access data sets authorization share data sets References 1 Hindricks G Potpara T Dagres N Bax JJ Boriani G Dan GA et al 2020 ESC Guidelines diagnosis management atrial fibrillation developed collaboration European Association CardioThoracic Surgery EACTS Eur Heart J 2021 42373498 2 Vassallo P Trohman RG Prescribing amiodarone JAMA 20072981312 3 Um KJ McIntyre WF Healey JS Mendoza PA Koziarz A Amit G et al Pre post treatment amiodarone elective electrical cardioversion atrial fibrillation systematic review metaanalysis Europace 20192185663 4 Bartalena L Bogazzi F Chiovato L HubalewskaDydejczyk A Links TP Vanderpump M 2018 European Thyroid Association ETA Guidelines management amiodaroneassociated thyroid dysfunction Eur Thyroid J 201875566 5 Basaria S Cooper DS Amiodarone thyroid Am J Med 200511870614 6 Trohman RG Sharma PS McAninch EA Bianco AC Amiodarone thyroid physi ology pathophysiology diagnosis management Trends Cardiovasc Med 201929 28595 Amiodarone thyroid dysfunction 299 7 le Heuzey JY Ferari GM Radzik D Santini M Zhu J Davy JM A shortterm rando mized doubleblind parallelgroup study evaluate efficacy safety drone darone versus amiodarone patients persistent atrial fibrillation DIONYSOS study J Cardiovasc Electrophysiol 201021597605 8 Yagishita A Hachiya H Kawabata M Nakamura T Sugiyama K Tanaka Y et al Amiodaroneinduced thyrotoxicosis late amiodarone withdrawal Circ J 2013 772898903 9 Burgess C Blaikie A Ingham T Robinson G Narasimhan S Monitoring use amio darone compliance guidelines Intern Med J 20063628993 10 Mihajlovic M Mihajlovic A Marinkovic M Kovacevic V Simic J Mujovic N et al Main determi nants physiciandriven amiodarone discontinuation clinical practice Europace 202123 euab116051 11 Trip MD Wiersinga W Plomp TA Incidence predictability pathogenesis amiodaroneinduced thyrotoxicosis hypothyroidism Am J Med 19919150711 12 Rose EP Thyroid dysfunction chronic amiodarone therapy J Am Coll Cardiol 1987917583 13 Kinoshita S Hayashi T Wada K Yamato M Kuwahara T Anzai T et al Risk factors amiodaroneinduced thyroid dysfunction Japan J Arrhythm 20163247480 14 Bouvy ML Heerdink ER Hoes AW Leufkens HGM Amiodaroneinduced thyroid dys function associated cumulative dose Pharmacoepidemiol Drug Saf 2002116016 15 Pedersen CB The Danish civil registration Scand J Public Health 201139225 16 Lynge E Sandegaard JL Rebolj M The Danish national patient register Scand J Public Health 201139303 17 Kildemoes HW Sørensen HT Hallas J The Danish national prescription registry Scand J Public Health 2011393841 18 Brandt F Thvilum M Almind D Christensen K Green A Hegedüs L et al Morbidity fore diagnosis hyperthyroidism nationwide registerbased study PLoS One 20138e66711 19 Gray RJ A class Ksample tests comparing cumulative incidence compet ing risk Ann Statist 198816114154 20 Connolly S Cairns J Gent M Roberts R Yusuf S Effect prophylactic amiodarone mortality acute myocardial infarction congestive heart failure Lancet 1997 350141724 21 Batcher EL Tang XC Singh BN Singh SN Reda DJ Hershman JM Thyroid function ab normalities amiodarone therapy persistent atrial fibrillation Am J Med 2007 1208805 22 Vorperian VR Havighurst TC Miller S January CT Adverse effects low dose amio darone metaanalysis J Am Coll Cardiol 1997307918 23 Sundbøll J Adelborg K Munch T Frøslev T Sørensen HT Bøtker HE et al Positive pre dictive value cardiovascular diagnoses Danish National Patient Registry val idation study BMJ Open 20166e012832 24 Kümler T Gislason GH Kirk V Bay M Nielsen OW Køber L et al Accuracy heart failure diagnosis administrative registers Eur J Heart Fail 2008 1065860 25 Schmidt M Schmidt SAJ Sandegaard JL Ehrenstein V Pedersen L Sørensen HT The Danish National Patient Registry review content data quality research poten tial Clin Epidemiol 2015744990 26 Quan H Li B Duncan Saunders L Parsons GA Nilsson CI Alibhai A et al Assessing val idity ICD9CM ICD10 administrative data recording clinical conditions unique dually coded database Health Serv Res 200843142441